Two main peptide strategies
Growth hormone (GH) release can be stimulated via the GHRH receptor (hypothalamic pathway) or the ghrelin receptor GHS-R1a (GHRP / ghrelin-mimetic pathway). Educational comparisons start there: sermorelin and CJC-1295-class molecules speak GHRH language; GHRP-2, GHRP-6, hexarelin, and ipamorelin speak ghrelin-receptor language.
GHRH analogs: sermorelin and CJC-1295
Sermorelin is essentially GHRH (1-29). CJC-1295 variants extend half-life concepts (including DAC albumin-binding ideas in some versions). Readers often confuse “CJC-1295 with DAC” and “modified GRF 1-29 / without DAC”—names in the marketplace are inconsistent, so mass and sequence confirmation matter.
GHRPs and selectivity
Early GHRPs can influence cortisol and prolactin in some contexts; ipamorelin is frequently described as more selective. That selectivity story is a major reason for its popularity in secondary literature and forums.
Why MK-677 appears in the same searches
MK-677 (ibutamoren) is an oral ghrelin-receptor agonist small molecule, not a peptide. Search engines and users group it with peptide secretagogues because the receptor pathway overlaps.
Research design notes
GH-axis experiments must account for pulsatility, feedback via IGF-1, sleep and nutrition confounds, and assay timing. Single time-point GH measurements can mislead. Educational content should model scientific humility.
Sources and what they cover
These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.
- Teichman et al. (2006) — CJC-1295 in healthy adults
Human pharmacokinetic and GH/IGF-1 study of CJC-1295 with DAC; not evidence for every product sold as CJC-1295.
Relevant sections: GHRH analogs: sermorelin and CJC-1295
- Raun et al. (1998) — Ipamorelin, a selective growth hormone secretagogue
Original preclinical receptor and hormone-release work; does not validate consumer stacks or human recovery claims.
Relevant sections: GHRPs and selectivity
- Murphy et al. (1998) — Oral MK-677 and diet-induced catabolism
Small human endocrine study of a nonpeptide secretagogue; not approval or general muscle-building evidence.
Relevant sections: Why MK-677 appears in the same searches
FAQ
What is CJC-1295 with DAC?+
It refers to a long-acting GHRH-analog design using a Drug Affinity Complex intended to bind albumin and extend half-life. Marketplace naming varies—verify identity analytically.
Ipamorelin vs GHRP-6?+
Both are GHS-R agonists; ipamorelin is often described as more selective, while GHRP-6 is associated with stronger orexigenic signaling in many discussions. Primary literature should guide experimental choices.